2024-05-16 23:00:27 ET
Summary
- Pfizer's stock has struggled to recover since the pandemic, but its high dividend yield of 5.9% makes it an attractive option for income investors.
- The company faces risks from upcoming patent expiries and the impact of rising interest rates on its debt and ability to invest in research and development.
- Despite these challenges, Pfizer's valuation metrics suggest it is attractively priced, and a dividend discount model estimates a potential upside of over 30% from the current price level.
Overview
Pfizer ( PFE ) (PFE:CA) has struggled to gain any sort of recovery momentum since it suffered losses in revenue coming off the tail end of the pandemic. In addition, the upcoming patent expiries seem to be a source of concern for many investors here as we try to figure out how PFE will whether that storm. I previously covered PFE back in January and rated it a Strong Buy, and the total return since then has been mostly flat....
Read the full article on Seeking Alpha
For further details see:
Pfizer: Potential Double-Digit Upside Combined With High Dividend Yield